Yup, that was it.
>>Geron says the FDA didn't grant its request for a priority review of imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes and instead assigned a standard review and target action date of June 16, 2024. Geron says the agency also plans to hold an advisory committee meeting as part of its review. The FDA had previously granted fast-track designation to imetelstat, paving the way for Geron to seek priority review, which shortens the FDA review period. Geron says that pending an FDA green light, it expects a U.S. imetelstat launch by the end of June 2024. Geron up 2.7% premarket to $2.70.
News 
Market Data 
Discover 
